Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival
暂无分享,去创建一个
O. Alter | Huanming Yang | Kui Wu | J. Bowen | J. Gastier-Foster | J. Barnholtz-Sloan | Kristen Leraas | K. Devine | Matthew W. Bradley | Sri Priya Ponnapalli | H. Hanson | Huijuan Luo | C. Wittwer | B. Milash | R. Jensen | Fuqiang Li | C. Palmer | S. Coppens | Shipei Qiu | K. Leraas | Jay Bowen
[1] O. Alter,et al. GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum , 2019, APL bioengineering.
[2] Orly Alter,et al. Mathematically universal and biologically consistent astrocytoma genotype encodes for transformation and predicts survival phenotype , 2018, APL bioengineering.
[3] J. Olsen,et al. Molecular basis of Tousled-Like Kinase 2 activation , 2018, Nature Communications.
[4] Andrea J. Liu,et al. DNA Damage Follows Repair Factor Depletion and Portends Genome Variation in Cancer Cells after Pore Migration , 2017, Current Biology.
[5] R. Elashoff,et al. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy , 2016, Neuro-oncology.
[6] Jill S Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.
[7] O. Alter,et al. Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition , 2016, PloS one.
[8] E. Miyaoka,et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.
[9] R. Schiff,et al. Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint , 2016, Molecular Cancer Research.
[10] S. Grossman,et al. Published glioblastoma clinical trials from 1980 to 2013: Lessons from the past and for the future. , 2016 .
[11] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[12] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[13] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[14] Orly Alter,et al. Tensor GSVD of Patient- and Platform-Matched Tumor and Normal DNA Copy-Number Profiles Uncovers Chromosome Arm-Wide Patterns of Tumor-Exclusive Platform-Consistent Alterations Encoding for Cell Transformation and Predicting Ovarian Cancer Survival , 2015, PloS one.
[15] Michael Hay,et al. Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.
[16] Henry Brem,et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. , 2014, Neuro-oncology.
[17] F. Collins,et al. First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.
[18] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[19] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[20] M. Delorenzi,et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.
[21] T. Cloughesy,et al. Impact of 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective , 2012, The Journal of Nuclear Medicine.
[22] Orly Alter,et al. GSVD Comparison of Patient-Matched Normal and Tumor aCGH Profiles Reveals Global Copy-Number Alterations Predicting Glioblastoma Multiforme Survival , 2012, PloS one.
[23] Charles R. Johnson,et al. Matrix Analysis, 2nd Ed , 2012 .
[24] O. Alter,et al. A Higher-Order Generalized Singular Value Decomposition for Comparison of Global mRNA Expression from Multiple Organisms , 2011, PloS one.
[25] Ryan Mills,et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants , 2011, Nature Biotechnology.
[26] Tomas W. Fitzgerald,et al. Origins and functional impact of copy number variation in the human genome , 2010, Nature.
[27] Sharon J. Diskin,et al. Copy number variation at 1q21.1 associated with neuroblastoma , 2009, Nature.
[28] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[29] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[30] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[31] Th. Boveri,et al. Concerning the Origin of Malignant Tumours , 2008 .
[32] Elizabeth Eisenhauer,et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.
[33] J. Lupski,et al. Genomic rearrangements and sporadic disease , 2007, Nature Genetics.
[34] Shmuel Friedland,et al. A New Approach to Generalized Singular Value Decomposition , 2005, SIAM J. Matrix Anal. Appl..
[35] D. Botstein,et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] Ivan Smirnov,et al. Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma , 2005, Clinical Cancer Research.
[37] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[38] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[39] K. Kurisu,et al. O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications , 2005, Journal of Neuro-Oncology.
[40] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[41] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Botstein,et al. Generalized singular value decomposition for comparative analysis of genome-scale expression data sets of two different organisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[43] G. Boulianne,et al. Identification of a novel family of putative methyltransferases that interact with human and Drosophila presenilins. , 2001, Gene.
[44] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[45] A. Friedman,et al. Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. , 2000, Neuro-oncology.
[46] Robert A. Weinberg,et al. Creation of human tumour cells with defined genetic elements , 1999, Nature.
[47] Bert Vogelstein,et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 , 1996, Nature.
[48] C. Sommer,et al. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[49] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[50] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[51] S. Smith,et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[52] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[53] M. Netsky,et al. The longevity of patients with glioblastoma multiforme. , 1950, Journal of neurosurgery.